Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rein Therapeutics ( (RNTX) ) has issued an update.
On July 23, 2025, Rein Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, which was previously adjourned on June 24, 2025. During this meeting, stockholders elected William C. Fairey as a Class II director for a three-year term expiring at the 2028 Annual Meeting. Additionally, stockholders approved, on a non-binding advisory basis, the company’s named executive officer compensation.
The most recent analyst rating on (RNTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.
Spark’s Take on RNTX Stock
According to Spark, TipRanks’ AI Analyst, RNTX is a Underperform.
Rein Therapeutics is experiencing severe financial difficulties, with persistent negative net income and cash flows. The technical analysis suggests bearish momentum with potential near-term volatility. The negative P/E ratio and lack of dividends further highlight the company’s weak financial position. The overall outlook for the stock is challenging, with significant risks outweighing potential rewards.
To see Spark’s full report on RNTX stock, click here.
More about Rein Therapeutics
Average Trading Volume: 38,352
Technical Sentiment Signal: Sell
Current Market Cap: $30.57M
For detailed information about RNTX stock, go to TipRanks’ Stock Analysis page.